OssDsign (OSSD) ABGSC Investor Days summary
Event summary combining transcript, slides, and related documents.
ABGSC Investor Days summary
4 Dec, 2025Business overview and strategy
Focused on property with three business areas: investment management, principal investments, and corporate finance.
SEK 160 billion in AUM, SEK 2.5 billion in revenue, operations in 12 countries, assets in 16.
Nearly 60% of revenues are recurring, providing stability and a key KPI for growth.
Pan-European platform with a strong brand and 35+ years of history.
Sustainability and local expertise are central to client relationships and investments.
Recent changes and priorities
Integrating principal investments into core operations to clarify recurring fees and returns.
Using balance sheet for co-investments to grow AUM and secure more recurring revenues.
Revitalized corporate finance during slow market, focusing on efficiency and scalability.
Continued focus on scalable pan-European products for institutional investors.
Market environment and financials
Transactional volumes are recovering slowly after a sharp decline, impacting variable income.
Investment management is the core growth engine, with AUM growing over 15% annually since 2015.
AUM growth has continued through asset management mandates despite limited fund inflows.
Principal investments now focus on minority stakes (5-10%) in partnerships, not full ownership.
Maintained solid cash position by exiting markets early and adapting operations.
Latest events from OssDsign
- Sales up 45% to SEK 180.2M, 96.3% margin, U.S. expansion, aiming for SEK 400M by 2028.OSSD
Q4 20253 Feb 2026 - Q2 net sales up 143%, gross margin at 93.2%, and major U.S. contracts secured.OSSD
Q2 202423 Jan 2026 - Q3 2024 delivered 114% sales growth, 96.9% gross margin, and narrowed losses.OSSD
Q3 202415 Jan 2026 - Record growth and high margins drive rapid U.S. expansion in orthobiologics.OSSD
ABGSC Investor Days12 Jan 2026 - Sales up 107% and gross margin above 95%, with strong U.S. growth and improved cash flow.OSSD
Q4 20248 Jan 2026 - SEK 158M raised to fund U.S. expansion, targeting SEK 400M+ sales and profitability by 2028.OSSD
Strategy Update27 Nov 2025 - Q2 sales up 73% at constant FX, gross margin 96.8%, and SEK 160M raised for U.S. growth.OSSD
Q2 202523 Nov 2025 - Sales up 65%, clinical data strong, and U.S. market access at 10% with major growth ahead.OSSD
ABGSC Investor Days21 Nov 2025 - Record 65% sales growth, 96.4% margin, and clinical milestones drive strong U.S. momentum.OSSD
Q1 202517 Nov 2025